Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and distribution.
Gilead has at long last won US approval of its hepatitis D treatment Hepcludex, which the FDA previously rejected over issues with its manufacturing and …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA approves Hepcludex for chronic hepatitis D
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test - Guardant Health (NASDAQ:GH)
